By Fineline Cube Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China-based Clinical Research Organization (CRO), announced today a private placement of up to 30% of its total share capital, raising RMB 447.73 million (approximately USD 66 million) to fund strategic expansion initiatives across its integrated pharmaceutical services platform.
Capital Raise Details
| Component | Detail |
|---|---|
| Company | Boji Medical Technology Co., Ltd. (SHE: 300404) |
| Transaction Type | Private placement |
| Equity Issued | Up to 30% of total share capital |
| Proceeds | RMB 447.73 million (USD 66 million) |
| Primary Use | Strategic infrastructure and capability expansion |
Strategic Investment Allocation
Drug Evaluation Center Expansion & Upgrade
- Enhanced Capabilities: Strengthened pharmacology, toxicology, and safety evaluation services
- Strategic Integration: Completes integrated layout spanning innovative drug R&D, drug evaluation, clinical research, regulatory filing, and CDMO services
- Capacity Increase: Expanded throughput for preclinical and non-clinical studies
Innovative Traditional Chinese Medicine (TCM) R&D
- Pipeline Acceleration: Expedited development of proprietary TCM innovative drug candidates
- Capability Enhancement: Elevated TCM-specific drug discovery and development expertise
- Differentiation Strategy: Leverages China’s unique TCM heritage in modern drug development framework
Intelligent Integrated Big Data Platform
- Digital Transformation: Significant improvement in pharmaceutical R&D digital capabilities
- Data Integration: Unified platform connecting preclinical, clinical, and regulatory data streams
- Operational Efficiency: Enhanced analytics and decision-making across the drug development lifecycle
SMO Center Construction
- Service Scale: Comprehensive enhancement of Site Management Organization (SMO) service capacity
- Execution Efficiency: Improved clinical trial site management and patient recruitment capabilities
- One-Stop Solution: Strengthened end-to-end CRO service offering from discovery through commercialization
Market Context
- China CRO Market: Valued at USD 12.8 billion in 2025 with projected CAGR of 18.5% through 2030
- Integrated Services Trend: Increasing demand for comprehensive CRO solutions covering the entire drug development continuum
- TCM Innovation: Growing government support for modernizing traditional Chinese medicine through scientific validation
- Digital Transformation: Accelerating adoption of big data and AI technologies across Chinese pharmaceutical R&D landscape
Forward-Looking Statements
This brief contains forward-looking statements regarding capital allocation, strategic initiatives, market opportunities, and business expansion plans. Actual results may differ due to risks including regulatory changes, competitive dynamics, execution challenges, and macroeconomic conditions affecting the Chinese biopharmaceutical sector.-Fineline Info & Tech